Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Issues related to pharmaceutical pricing and reimbursement.
Issues related to formulary tiering and Medicare rebates.
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Issues related to drug innovation and access to medicines.
Duration: January 2, 2018
to
present
General Issues: Copyright/Patent/Trademark , Disaster Planning/Emergencies , Health Issues , Medicare/Medicaid , Pharmacy , Science/Technology , Manufacturing , Trade (Domestic & Foreign)
Spending: about $3,133,331 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, U.S. Trade Representative (USTR), U.S. Agency for International Development (USAID)
Related Foreign Entities:
Lupin Limited (Mumbai, IND); contribution to lobbying: $33000; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Shawn Brown Esq. Vice President of Government Affairs
Shawn Brown Vice President of Government Affairs
VP of Government Affairs
VP Government Affairs
VP Government Affaris
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
In Q4, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Jan. 10.
Original Filing: 301523214.xml
Lobbying Issues
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Issues related to pharmaceutical pricing and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to formulary tiering and Medicare rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug innovation and access to medicines.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Oct. 16, 2023.
Original Filing: 301501424.xml
Lobbying Issues
Issues related to patent thickets, patentability standards and IP influencing applications for drug marketing approval.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to addressing drug shortages, including stockpiling and improvements to the drug supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Disaster Planning/Emergencies
Lobbying Issues
Issues related to pharmaceutical pricing and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to formulary tiering and Medicare rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to finished dose pharmaceutical reimbursement, pricing transparency, and drug disposal.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug innovation and access to medicines.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Aug. 8, 2023.
Original Filing: 301494680.xml
Lobbying Issues
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Lupin Pharmaceuticals Inc. did not lobby on any trade issues this quarter.
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lupin Pharmaceuticals Inc. did not lobby on any Disaster Planning/Emergencies legislation this quarter.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2023
In Q1, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on May 3, 2023.
Original Filing: 301469956.xml
Lobbying Issues
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114).
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
The Inflation Reduction Act; provisions regarding negotiated prices for drugs. The BLOCKING Act, or the Smith-Braun amendment regarding changes to the 180-day exclusivity provision of the Hatch-Waxman Act (S. 1114)
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
Lupin Pharmaceuticals Inc. did not lobby on any trade issues this quarter.
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lupin Pharmaceuticals Inc. did not lobby on any Disaster Planning/Emergencies legislation this quarter.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2022
In Q4, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Jan. 30, 2023.
Original Filing: 301445256.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2022
In Q3, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Oct. 24, 2022.
Original Filing: 301420885.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2022
In Q2, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Aug. 23, 2022.
Original Filing: 301399233.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2022
In Q1, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on May 25, 2022.
Original Filing: 301375574.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2021
In Q4, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Jan. 31, 2022.
Original Filing: 301340365.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping. BLOCKING Act. Medicare drug price negotiations. Drug price inflation rebate penalty in Medicare.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2021
In Q3, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Nov. 3, 2021.
Original Filing: 301317189.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2021
In Q2, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on July 12, 2021.
Original Filing: 301275012.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2021
In Q1, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on April 30, 2021.
Original Filing: 301270011.xml
Lobbying Issues
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Lobbying Issues
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2020
LUPIN PHARMACEUTICALS INC amended a lobbying report for in-house lobbying in Q42020 on Feb. 22, 2021
Original Filing: 301248871.xml
Lobbying Issues
BLOCKING Act
Patent Settlements
Pharmaceutical Supply chain
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Patent Settlments
BLOCKING Act (H.R. 938).
Pharmaceutical Supply Chain
Medicaid & Medicare
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2020
In Q4, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Dec. 30, 2020.
Original Filing: 301228259.xml
Lobbying Issues
BLOCKING Act
Patent Settlements
CREATES Act
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2020
In Q3, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Nov. 5, 2020.
Original Filing: 301226173.xml
Lobbying Issues
BLOCKING Act
Patent Settlements
CREATES Act
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2020
LUPIN PHARMACEUTICALS INC amended a lobbying report for in-house lobbying in Q22020 on Sept. 2, 2020
Original Filing: 301206118.xml
Lobbying Issues
BLOCKING Act
Patent Settlements
CREATES Act
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2020
In Q2, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on July 14, 2020.
Original Filing: 301187557.xml
Lobbying Issues
BLOCKING Act
Patent Settlements
CREATES Act
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2020
In Q1, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on June 2, 2020.
Original Filing: 301183955.xml
Lobbying Issues
BLOCKING Act
Patent Settlements
CREATES Act
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
CARES Act
HEROES Act
CARES Act 2.0
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Ensuring the USMCA is framework for US-UK agreement particularly in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Lobbying for AAM's "Blue Print for Enhancing Security of the Supply Chain". No legislation adopts this yet.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2019
In Q4, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Jan. 2, 2020.
Original Filing: 301102962.xml
Lobbying Issues
Lobbying to maintain IPR by PTO.
BLOCKING Act
FAIR Act (Tina Smith D-MI)
TERM Act
Patent Settlements
CREATES Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
Preserve Access to Affordable Generics Act (S. 64).
Hatch-Waxman Integrity Act (S 344).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2019
In Q3, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Nov. 20, 2019.
Original Filing: 301091564.xml
Lobbying Issues
Lobbying to maintain IPR by PTO.
BLOCKING Act
FAIR Act (Tina Smith D-MI)
TERM Act
Patent Settlements
CREATES Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
Preserve Access to Affordable Generics Act (S. 64).
Hatch-Waxman Integrity Act (S 344).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2019
In Q2, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Sept. 30, 2019.
Original Filing: 301062651.xml
Lobbying Issues
Lobbying to maintain IPR by PTO.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
Preserve Access to Affordable Generics Act (S. 64).
Hatch-Waxman Integrity Act (S 344).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
In Q1, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on May 9, 2019.
Original Filing: 301040616.xml
Lobbying Issues
Lobbying to maintain IPR by PTO.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S. 794).
BLOCKING Act (H.R. 938).
Preserve Access to Affordable Generics Act (S. 64).
Hatch-Waxman Integrity Act (S 344).
Agencies Lobbied
U.S. Senate
Lobbying Issues
The additional CPI penalty on generic drugs within Medicaid.
Agencies Lobbied
U.S. Senate
Lobbying Issues
New laws governing opioids.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Not applicable this quarter.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Changes to the USMCA to make agreement consistent with balance in US law in IP related provisions.
Agencies Lobbied
U.S. Trade Representative (USTR)
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2018
In Q4, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Jan. 23, 2019.
Original Filing: 301018306.xml
Lobbying Issues
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues.
Patent settlements legislation
USMCA - regarding IP standards in USMCA.
IPR - regarding PTO authority to administrative review of patents.
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity.
Patent settlements legislation.
Agencies Lobbied
U.S. Senate
Lobbying Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Medicare/Medicaid
Lobbying Issues
USMCA - regarding IP chapter
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2018
In Q3, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on Oct. 15, 2018.
Original Filing: 300985139.xml
Lobbying Issues
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues.
PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims
CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity.
CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2018
In Q2, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on July 18, 2018.
Original Filing: 300967568.xml
Lobbying Issues
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues.
PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims
CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity.
CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
1st Quarter, 2018
In Q1, LUPIN PHARMACEUTICALS INC had in-house lobbyists. The report was filed on April 25, 2018.
Original Filing: 300959109.xml
Lobbying Issues
CREATES Act (S.974/H.R.2212) - addresses REMS and market entry issues.
PACED Act (S.2514) - restores power to PTO to review patents regardless of sovereign immunity claims
CARA 2.0 (S.2456/H.R.5311) - addresses opioid abuse crisis
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
CREATES Act (S.974/H.R.2212) - Addresses REMS and market entry issues.
PACED Act (S.2514) - Restores PTO's authority to review patents despite assertion of sovereign immunity.
CARA 2.0 (S.2456/H.R.5311) - Addresses opioid crisis.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
1st Quarter, 2018
LUPIN PHARMACEUTICALS INC filed a lobbying registration on March 8, 2018 for in-house lobbying efforts, effective Jan. 2, 2018.
Original Filing: 300941138.xml
Issue(s) they said they’d lobby about: CREATES Act, biosimilars regulation, drug pricing, intellectual property issues related to pharmaceuticals .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...